New Immunotherapy Advances Presented at the AACR Annual Meeting 2015
Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial...
Category: Meetings
Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial...
Hear from AACR President Carlos L. Arteaga, MD, and Annual Meeting Program Committee Chairperson Lewis C. Cantley, PhD, about...
With the start of the AACR Annual Meeting 2015 only four days away, the organization is ramping up its...
In addition to providing a forum for attendees to learn, network, and share information and ideas, the Annual Meeting...
Guest Post by Raymond DuBois, MD, PhD Arizona State University Biodesign Institute
In our first post of this Behind the Scenes series, you read about the years of planning that go...
When the AACR Annual Meeting 2015 begins April 18 in Philadelphia, more than 18,500 attendees will flow seamlessly through...
Guest Post by Matthew J. Sikora, PhD University of Pittsburgh Cancer Institute
Advances against cancer that make it to the clinic are a result of many years of hard work by...
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new treatments for cancer continued last week...